Floatz logo

Anti-Cd19/Cd20/Cd22 Car T-Cells

Recurrent High Grade B-Cell Lymphoma

Sumithira VasuCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Recurrent High Grade B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Mayo Clinic
Phase 2B
Fludarabine
Roswell Park Cancer Institute
Phase 2B
Anakinra
M.D. Anderson Cancer Center
Phase 2B
Monomethyl Fumarate
M.D. Anderson Cancer Center
Phase 2CCC
Busulphan
M.D. Anderson Cancer Center
Phase 2CCC

View all 16 →

Same molecule, other indications

Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:

Recurrent B Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent B-Cell Prolymphocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →